Researchers unveiled a senolytic therapeutic approach for pancreatic ductal adenocarcinoma (PDAC) that targets senescent tumor‑supporting cells and the KRAS–RB1 interaction, producing tumor control in preclinical models. The work sidesteps direct KRAS inhibition by removing senescent stromal populations that sustain PDAC growth and therapy resistance. The approach, reported in recent coverage of translational oncology breakthroughs, offers a new angle to tackle PDAC’s dense microenvironment and provides a candidate modality for combination with cytotoxic or immunotherapeutic regimens.